
News|Articles|September 1, 2001
Trio of new studies help clarify role of abciximab
Abciximab reduces nonfatal outcomes as part of a new reperfusion regimen for acute myocardial infarction (MI) but appears not to benefit patients with acute coronary syndromes who don't undergo early revascularization.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Growth of GLP-1 therapies has reshaped the market | PBMI 2026
2
Judi Health, Employers Health team up to launch new PBM solution
3
Amy Wadstrom, RPh, on mid-size PBMs and leaving the ‘big three’ | PBMI 2026
4
Amivantamab, chemo combo shows nearly 3-year survival in EGFR exon 20 lung cancer
5
























